Author:
Maxwell Jessica E.,Naraev Boris,Halperin Daniel M.,Choti Michael A.,Halfdanarson Thorvardur R.
Funder
TerSera Therapeutics, LLC
Lexicon Pharmaceuticals, Inc.
Publisher
Springer Science and Business Media LLC
Reference114 articles.
1. Liu EH, Solorzano CC, Katznelson L, et al. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21(5):534–45.
2. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production, and survival. Annal Surg. 1987;206(2):115–25.
3. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
4. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.
5. Quinlivan JK, Roberts WA. Intraoperative octreotide for refractory carcinoid-induced bronchospasm. Anesth Analg. 1994;78(2):400–2.